drugset
Drugs / Recombinant SARS-CoV-2 Vaccine (CHO cell)
last change Aug 2023 re-read 3 minutes ago

Recombinant SARS-CoV-2 Vaccine (CHO cell)

Vaccine

Developed for
COVID-19
Investigated by
Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd. · Lanzhou Institute of Biological Products Co., Ltd · National Vaccine and Serum Institute, China · Zhengzhou University

Trials 1

today NCT04869592 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04869592 Apr 2021 → Aug 2023 COVID-19 National Vaccine and Serum Institute, China Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant SARS-CoV-2 Vaccine (CHO cell) ClinicalTrials.gov intervention name — accepted as the source's own label NCT04869592 ↗
Modality Vaccine “Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm” NCT04869592 ↗
Route Intramuscular “Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm” NCT04869592 ↗